Fideuram Asset Management Ireland dac Invests $2.84 Million in Abbott Laboratories $ABT

Key Points

• Fideuram Asset Management Ireland dac opened a new position in Abbott Laboratories in the fourth quarter, buying 20,866 shares valued at about $2.84 million.
• Abbott’s recent operating results were solid, with the company reporting $1.15 EPS and $11.16 billion in revenue, both slightly ahead of expectations; revenue rose 7.8% year over year.
• Analysts remain generally constructive despite some lower price targets, with the stock holding a Moderate Buy consensus and an average target price of $119.09.

Fideuram Asset Management Ireland dac bought a new position in Abbott Laboratories (NYSE:ABT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,866 shares of the healthcare product maker's stock, valued at approximately $2,843,000.

Several other hedge funds also recently made changes to their positions in the company. American National Bank of Texas lifted its stake in shares of Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker's stock worth $427,000 after acquiring an additional 79 shares during the period. Nia Impact Advisors LLC lifted its stake in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock worth $504,000 after acquiring an additional 79 shares during the period. Connable Office Inc. lifted its stake in shares of Abbott Laboratories by 0.5% in the 3rd quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker's stock worth $2,015,000 after acquiring an additional 81 shares during the period. Park Place Capital Corp lifted its stake in shares of Abbott Laboratories by 11.0% in the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker's stock worth $102,000 after acquiring an additional 81 shares during the period. Finally, Lantern Wealth Advisors LLC lifted its stake in shares of Abbott Laboratories by 1.7% in the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker's stock worth $674,000 after acquiring an additional 84 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Abbott Laboratories Trading Down 1.1%

Shares of ABT opened at $85.36 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a 50 day simple moving average of $94.46 and a 200-day simple moving average of $110.69. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The stock has a market cap of $148.68 billion, a price-to-earnings ratio of 23.91, a price-to-earnings-growth ratio of 1.44 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. During the same period last year, the company posted $1.09 EPS. The company's revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research note on Tuesday, April 21st. The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research note on Wednesday. UBS Group reduced their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating for the company in a research note on Monday, April 20th. TD Cowen decreased their target price on Abbott Laboratories from $137.00 to $115.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Finally, Jefferies Financial Group lowered their target price on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $119.09.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares of the company's stock, valued at $12,053,953.78. This trade represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.